Elanco's monoclonal antibody therapy, Trutect, received a conditional license from the federal agency in 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback